Atezolizumab in Combination with Bevacizumab


Atezolizumab in Combination with Bevacizumab in Untreated mRCC: Updated Analysis of IMmotion150 Study [LBA39]
Powles T, et al. 

The efficacy and safety of atezolizumab (anti-PD-L1) + bevacizumab (anti-VEGF) compared to sunitinib (TKI) in first-line (1L) metastatic renal-cell carcinoma (mRCC) were studied in the open-label, randomized, phase II IMmotion150 study (NCT01984242). Primary analysis (median follow-up, 20.7 mo) was previously reported at ASCO GU 2017. Updated analysis (median follow-up, 25.7 mo) has just been presented at ESMO 2017.

Results:
This updated analysis showed clinically meaningful benefit in PFS with atezolizumab + bevacizumab vs. sunitinib in both PD-L1+ and ITT patients. No new safety signals were detected with this updated analysis.

Data showing investigator (INV)-assessed PFS in both PD-L1+ and ITT patients are summarized as below:

*PD-L1+ was defined as PD-L1 expression ≥ 1% on tumor-infiltrating immune cells (IC) measured by VENTENA SP142 IHC assay.

Conclusion:
These data supported the combination use of atezolizumab (anti-PD-L1) + bevacizumab (anti-VEGF) in 1L mRCC. Clinical benefit of this combination did not come at the expense of increased symptom burden. This combination will be further evaluated in the ongoing phase III IMmotion151 study (NCT02520821).

 

http://oncologypro.esmo.org/Meeting-Resources/ESMO-2017-Congress/IMmotion150-Novel-Radiological-Endpoints-and-Updated-Data-From-a-Randomized-Phase-II-Trial-Investigating-Atezolizumab-atezo-With-or-Without-Bevacizumab-bev-vs-Sunitinib-sun-in-Untreated-Metastatic-Renal-Cell-Carcinoma-mRCC

 

Felix Choi
Associate Manager, Medical Affairs
Cancer Immunotherapy
e-mail: felix.choi@roche.com